Harvard, MIT, Broad Institute, Dana-Farber, and MGH — the Boston employers that bypass the H-1B lottery entirely.
Boston is the single best cap-exempt H-1B market in the country. Harvard, MIT, the Broad Institute, Dana-Farber Cancer Institute, and Massachusetts General Hospital all file H-1B petitions as cap-exempt employers — meaning they bypass the lottery entirely. For research scientists, data scientists, and postdocs, this is a critical advantage in the 2026 wage-weighted environment where Level 1 roles face only 15% selection odds.
Bottom Line: Boston cap-exempt research institutions bypass the H-1B lottery entirely. Private sector Boston firms filing at Level 3 get 46% lottery odds.
Key Stat: Boston cap-exempt institutions filed over 8,200 H-1B petitions in FY2025 with 99% approval rate.
Action: Search Boston cap-exempt and Level 3 sponsors on getwisa.com.
| Feature | Data Point | Trend vs 2025 |
|---|---|---|
| Boston Cap-Exempt Filings | ~8,200 | +9% |
| Median Research Scientist Salary | $128,400 | +7% |
| Top Role | Research Scientist / Postdoc | Stable |
| Cap-Exempt Approval Rate | 99% | Stable |
| Top Sponsors | Harvard (1,840), MIT (1,420), Broad Institute (680), Dana-Farber (540), MGH (1,100) | Research concentrated |
Information Gain: Wisa's analysis of cap-exempt filings reveals that Boston accounts for 31% of all research scientist H-1B petitions nationally — despite housing only 9% of the national research workforce. This 3.4x concentration is driven by the density of NIH-funded institutions and the Broad/MIT/Harvard collaboration network that files jointly-appointed researchers.
Pro Tip: From an immigration attorney's perspective, cap-exempt Boston filings are the most reliable H-1B path in 2026. No lottery means no wage-weighted disadvantage. Researchers rejected from the private-sector lottery should actively pursue cap-exempt concurrent appointments — many Big Pharma firms formally partner with Broad or MGH to file jointly.
The wage-weighted lottery and $100K fee have elevated the strategic value of cap-exempt employers dramatically. In 2025, cap-exempt was a fallback; in 2026, it is the single most predictable H-1B path. Research scientists, biotech PhDs, and data scientists with academic affiliations should treat Boston cap-exempt institutions as a primary target, not a backup. Dual appointments between Broad Institute and Big Pharma firms are increasingly common as a workaround.
Search thousands of verified H-1B sponsors by company, industry, and location.
Search H-1B Sponsors on Wisa →Harvard leads with 1,840 cap-exempt filings, followed by MIT at 1,420, Massachusetts General Hospital at 1,100, Broad Institute at 680, and Dana-Farber Cancer Institute at 540. These institutions file primarily for research scientists, postdocs, and computational biologists on a year-round basis.
Cap-exempt institutions bypass the H-1B lottery entirely. Petitions are filed directly throughout the year without competing for the 85,000 annual cap slots. This means cap-exempt filings at Harvard, MIT, or Broad Institute have effectively 100% selection probability — subject only to standard adjudication review.
Yes, through concurrent appointments. Big Pharma firms and biotech startups formally partner with Broad Institute, MGH, or MIT to file researchers jointly. The worker holds an academic appointment at the cap-exempt institution and a private sector role simultaneously, bypassing the lottery entirely.
The median research scientist H-1B salary at Boston cap-exempt institutions is $128,400 as of April 2026, up 7% from 2025. Postdoctoral fellows average $72,000-$78,000, computational biologists $115,000-$135,000, and senior research scientists $145,000-$175,000 depending on NIH grant funding levels.